VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Lilly's Retevmo (Selpercatinib) Shows 83% Reduction in Risk of Recurrence or Death in Early-Stage RET Fusion-Positive Lung Cancer
Lilly's Retevmo (Selpercatinib) Shows 83% Reduction in Risk of Recurrence or Death in Early-Stage RET Fusion-Positive Lung Cancer
May 31, 2026 20:01 CST Updated 22:00
Share:
